Two senior executives join the company and will be located in Morristown, New Jersey
Newron Pharmaceuticals, an Italian research and development company focused on novel central nervous system (CNS) and pain therapies, has started operations in the US.
Newron Pharmaceuticals US is located in Morristown, New Jersey.
The company, headquartered in Bresso, near Milan, recently submitted a New Drug Application to the US Food and Drug Administration for safinamide for the treatment of Parkinson’s disease.
The company is developing a portfolio of compounds in advanced clinical stages for orphan diseases of the CNS, in addition to a schizophrenia drug.
Newron Pharmaceuticals US will be responsible for interactions with the FDA and the conduct of clinical investigations of its compounds in the US.
Two senior industry executives have joined the company and will operate from the US office. They are: Stephen Graham, Executive Director Clinical Development, formerly Senior Director Clinical Development at Forest Research Institute, who has more than 20 years of experience in CNS clinical development including previous employment at Novartis and Boots; and William Leong, Senior Director Chemistry/Manufacturing/Controls (CMC), formerly Senior Director and Head of Process Chemistry at Celgene, also with over 20 years of experience at Celgene and Schering-Plough.
'Newron’s US operations in Morristown will play a key role in broadening our in-house resources in clinical development of CNS therapies, and in expanding our interactions with the FDA,' said Stefan Weber, CEO of Newron.
'Furthermore, the subsidiary will serve as the site for the future commercial operations of Newron for our clinical-stage portfolio of orphan compounds.'